Abstract 5204
Background
Microbiota has been linked to the development of multiple cancers through various mechanisms. In bladder cancer (BC), preliminary studies have found alterations in the urinary microbiota of patients with urothelial carcinoma in comparison with healthy individuals. However, the bladder microbiota (BMi) has not been explored. The aims of this study were to characterize the BMi in a cohort of BC patients, to explore differences in the BMi composition between tumor (T) and normal (N) mucosa, and to identify its correlation with clinicopathologic features.
Methods
A total of 58 samples obtained by cystectomy from 32 BC patients (frozen tumor tissues and normal appearing mucosa for 26 patients and 6 tumor tissues) from Hospital General de Elche Biobank (Spain) were included. DNAs isolated from bladder samples were used to perform 16S rRNA gene sequencing (V3 and V4 region). A paired-end 2 × 300 bp cycle run on Illumina MiSeq. Ribosomal Database Project Classifier was used for taxonomical assignment. Statistical analysis was performed using Rstudio platform. Groups of data were compared using Wilcoxon test and Mann Whitney test for 26T vs 26N (paired group) and 32T vs 26N (unpaired group), respectively.
Results
There were no statistically significant differences of diversity between T and N, but there were differences of richness between T and N at the genus level (Chao1 index, p = 0.049). Globally, the most abundant phylum was Firmicutes, followed by Bacteroidetes, Proteobacteria and Actinobacteria. We found that the microbial composition differed significantly between T and N in both groups. At the phylum level, while Cyanobacteria.Chloroplast (0.74% vs 2.44%; p = 0.025) was enriched in T, Actinobacteria were reduced in T. Principal component analysis based on the relative abundance of phylum (36.9% PC1 and 28.7% PC2 of explained variance) revealed a significant separation in bacterial community composition between tumor tissues associated with histological tumor grade (permanova grade =0.036).
Conclusions
Significant differences in the BMi composition associated with tumor grade were observed. Additional studies are needed to determine the role of BMi in the evolution of BC and its therapeutic implications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract